By disabling immune checkpoints, such as those regulated by cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or programmed cell death-1 (PD-1), cancer immunotherapies stimulate the activity of immune cells that can thereby promote the clearance of cancer cells (Waldman et al. 2020). Here, PDCD1 is linked to cancer.